RecruitingNCT07323784
NTX-1472 for social anxiety in adults
About this title
Read the official source — NCT07323784Researchers are comparing NTX-1472 and placebo, tracking side effects to assess safety and tolerability in adults with an anxiety condition.
Medication studyAges 18–65United States
Understand this study
What is this study about?
Researchers are comparing NTX-1472 and placebo, tracking side effects to assess safety and tolerability in adults with an anxiety condition.
Who could participate?
This study is for people with anxiety. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Encino and 10 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: December 9, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 100
- Sponsor
- Newleos Therapeutics, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07323784
- Official title
Show the full official title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of NTX-1472, a V1a Receptor Antagonist, in Adults With Social Anxiety Disorder
Recruitment & locations
RecruitingEncino · Los Angeles · Oceanside
8 more locations
- San Jose
- Jacksonville
- Tampa
- Boston
- Las Vegas
- Brooklyn
- Memphis
- Austin
A listed location does not confirm current availability.
Questions about this study
What is this study about?
Researchers are comparing NTX-1472 and placebo, tracking side effects to assess safety and tolerability in adults with an anxiety condition.
Who is behind this study?
The study sponsor is Newleos Therapeutics, Inc.
Does this study involve medication?
Yes. The study involves medication, including NTX-1472 and Placebo.
Who can participate?
This study is for people with anxiety. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
